MRMatthew V. Ronan

Matthew V. Ronan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew V. Ronan has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Medically ready for discharge: A multicenter Veterans Health Administration assessment of hospitalized patients

    by Michelle M. Guidry, Matthew Tuck, Joyce Akwe, Raj Sehgal, Elizabeth A. Schackmann, Heather S. Shaw, Ashley H. Sweeney, Albertine S Beard, Dustin J. Uhlenhopp, Nurit Harari, et al.

    Background: Patients may remain hospitalized despite being medically ready for discharge, some for prolonged periods. Delays in discharge may negatively impact patients and hospitals. Objective: To quantify the proportion of acute care general medicine patients in VHA hospitals who are medically ready for discharge but remain hospitalized due to major discharge barriers and to identify the major contributors. Methods: Cross‐sectional study of 21 VHA hospitals using a structured tool to collect data from inpatient medicine attending physicians about their patients and the hospital on a single day. Primary outcomes were the percentage of patients medically ready for discharge and those with “major discharge barriers” (medically ready for discharge ≥1 week). Secondary outcomes explored support needs, resources awaited, and major contributing factors. Results: Of 1,348 sampled patients, 41.9% ( n = 565, range 18.4%–64.7%) were medically ready for discharge, including 18.1% ( n = 244, range 0%–32%) who had major discharge barriers. For more than half of these patients, the intended discharge location was a long‐term care facility (41.9%, nursing home for custodial care; 9.7%, assisted living facility). The most identified support needs were assistance with ADLs and geriatric‐psychiatric care. Payor source and selection of discharge location were the most common resources awaited. Conclusions: Nearly one in five hospitalized veterans had major discharge barriers leading to prolonged hospitalization after they were medically ready for discharge. More than half were awaiting long‐term care placement. This was due to a lack of available post‐discharge resources and support. Multidisciplinary engagement to streamline processes and increase resources for post‐discharge facility placement is needed.

  • Why are we dropping the ball on treating alcohol use disorder in the hospital?

    by Rahul B. Ganatra, Matthew V. Ronan

  • Clinical progress note: Phenobarbital in the treatment of alcohol withdrawal syndrome

    by Thad E. Abrams, Matthew V. Ronan

    Alcohol withdrawal syndrome (AWS) is a common condition experienced by hospitalized patients. Practice patterns have evolved over time to include the use of phenobarbital, a barbiturate, as an adjunct to benzodiazepines or as an alternative monotherapy. The American Society of Addiction Medicine (ASAM) has recommended the use of phenobarbital in the management of AWS in certain clinical contexts. The current evidence base for the use of phenobarbital in AWS remains limited, though sufficient to demonstrate safety and efficacy as an alternative to benzodiazepines.


  • Medications for alcohol‐use disorder and follow‐up after hospitalization for alcohol withdrawal: A multicenter study

    by Nazima Allaudeen, Joyce Akwe, Cherinne Arundel, Joel C. Boggan, Peter Caldwell, Paul B. Cornia, Jessica Cyr, Erik Ehlers, Joel Elzweig, Patrick Godwin, et al.

    Background: Alcohol withdrawal is a common reason for admission to acute care hospitals. Prescription of medications for alcohol‐use disorder (AUD) and close outpatient follow‐up are commonly recommended, but few studies report their effects on postdischarge outcomes.Objectives: The objective of this study is to evaluate the effects of medications for AUD and follow‐up appointments on readmission and abstinence.Methods: This retrospective cohort study evaluated veterans admitted for alcohol withdrawal to medical services at 19 Veteran Health Administration hospitals between October 1, 2018 and September 30, 2019. Factors associated with all‐cause 30‐day readmission and 6‐month abstinence were examined using logistic regression.Results: Of the 594 patients included in this study, 296 (50.7%) were prescribed medications for AUD at discharge and 459 (78.5%) were discharged with follow‐up appointments, including 251 (42.8%) with a substance‐use clinic appointment, 191 (32.9%) with a substance‐use program appointment, and 73 (12.5%) discharged to a residential program. All‐cause 30‐day readmission occurred for 150 patients (25.5%) and 103 (17.8%) remained abstinent at 6 months. Medications for AUD and outpatient discharge appointments were not associated with readmission or abstinence. Discharge to residential treatment program was associated with reduced 30‐day readmission (adjusted odds ratio [AOR]: 0.39, 95% confidence interval [95% CI]: 0.18–0.82) and improved abstinence (AOR: 2.50, 95% CI: 1.33–4.73).Conclusions: Readmission and return to heavy drinking are common for patients discharged for alcohol withdrawal. Medications for AUD were not associated with improved outcomes. The only intervention at the time of discharge that improved outcomes was discharge to residential treatment program, which was associated with decreased readmission and improved abstinence.


  • Contemporary Management and Outcomes of Veterans Hospitalized With Alcohol Withdrawal: A Multicenter Retrospective Cohort Study

    by Matthew V. Ronan, Kirsha S. Gordon, Melissa Ma Skanderson, Michael Krug, Patrick Godwin, Daniel Heppe, Matthew Hoegh, Joel C. Boggan, Jeydith Gutierrez, Peter Md Kaboli, et al.

    Objectives: Few studies describe contemporary alcohol withdrawal management in hospitalized settings or review current practices considering the guidelines by the American Society of Addiction Medicine (ASAM). Methods: We conducted a retrospective cohort study of patients hospitalized with alcohol withdrawal on medical or surgical wards in 19 Veteran Health Administration (VHA) hospitals between October 1, 2018, and September 30, 2019. Demographic and comorbidity data were obtained from the Veteran Health Administration Corporate Data Warehouse. Inpatient management and hospital outcomes were obtained by chart review. Factors associated with treatment duration and complicated withdrawal were examined. Results: Of the 594 patients included in this study, 51% were managed with symptom-triggered therapy alone, 26% with fixed dose plus symptom-triggered therapy, 10% with front loading regimens plus symptom-triggered therapy, and 3% with fixed dose alone. The most common medication given was lorazepam (87%) followed by chlordiazepoxide (33%), diazepam (14%), and phenobarbital (6%). Symptom-triggered therapy alone (relative risk [RR], 0.68; 95% confidence interval [CI], 0.57–0.80) and front loading with symptom-triggered therapy (RR, 0.75; 95% CI, 0.62–0.92) were associated with reduced treatment duration. Lorazepam (RR, 1.20; 95% CI, 1.02–1.41) and phenobarbital (RR, 1.28; 95% CI, 1.06–1.54) were associated with increased treatment duration. Lorazepam (adjusted odds ratio, 4.30; 95% CI, 1.05–17.63) and phenobarbital (adjusted odds ratio, 6.51; 95% CI, 2.08–20.40) were also associated with complicated withdrawal. Conclusions: Overall, our results support guidelines by the ASAM to manage patients with long-acting benzodiazepines using symptom-triggered therapy. Health care systems that are using shorter acting benzodiazepines and fixed-dose regimens should consider updating alcohol withdrawal management pathways to follow ASAM recommendations.


  • Alcohol-Related Hospitalizations During the Initial COVID-19 Lockdown in Massachusetts: An Interrupted Time-Series Analysis

    by Matthew V Ronan

    The United States’ initial public health response to the COVID-19 pandemic included containment measures that varied by state but generally required closing or

  • Open Access

    Report of a Novel Molecular Profile in Malignant Insulinoma

    by Laura Burns, Bita Naimi, Matthew Ronan, Huihong Xu, Horst Christian Weber

    Pancreatic neuroendocrine tumors, or pNETs, represent a rare and clinically heterogenous subset of pancreatic neoplasms. One such pNET, the insulinoma, is found to be malignant in just 4% of all insulinomas. Due to the exceedingly uncommon occurrence of these tumors, there is controversy regarding the optimal evidence-based management for these patients. We therefore report on a 70-year-old male patient admitted with 3 months of episodic confusion with concurrent hypoglycemia. The patient was found to have inappropriately elevated endogenous insulin levels during these episodes, and somatostatin-receptor subtype 2 selective imaging revealed a pancreatic mass metastatic to local lymph nodes, spleen, and the liver. Fine needle aspiration of pancreatic and liver lesions confirmed the diagnosis of a low grade pancreatic neuroendocrine tumor. Molecular analysis of tumor tissue revealed a novel mutational profile consistent with pNET. The patient was initiated on octreotide therapy. However, treatment with octreotide alone demonstrated limited efficacy in controlling the patient’s symptoms, prompting consideration of other therapies.


  • Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines

    by Susan L. Calcaterra, Richard Bottner, Marlene Martin, Honora Englander, Zoe M. Weinstein, Melissa B. Weimer, Eugene Lambert, Matthew V. Ronan, Sergio Huerta, Tauheed Zaman, et al.

    Background: Hospitalizations related to the consequences of opioid use are rising. National guidelines directing in‐hospital opioid use disorder (OUD) management do not exist. OUD treatment guidelines intended for other treatment settings could inform in‐hospital OUD management.Objective: Evaluate the quality and content of existing guidelines for OUD treatment and management.Data Sources: OVID MEDLINE, PubMed, Ovid PsychINFO, EBSCOhost CINHAL, ERCI Guidelines Trust, websites of relevant societies and advocacy organizations, and selected international search engines.Study Selection: Guidelines published between January 2010 to June 2020 addressing OUD treatment, opioid withdrawal management, opioid overdose prevention, and care transitions among adults.Data Extraction: We assessed quality using the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument.Data Synthesis: Nineteen guidelines met the selection criteria. Most recommendations were based on observational studies or expert consensus. Guidelines recommended the use of nonstigmatizing language among patients with OUD; to assess patients with unhealthy opioid use for OUD using the Diagnostic Statistical Manual of Diseases—5th Edition criteria; use of methadone or buprenorphine to treat OUD and opioid withdrawal; use of multimodal, nonopioid therapy, and when needed, short‐acting opioid analgesics in addition to buprenorphine or methadone, for acute pain management; ensuring linkage to ongoing methadone or buprenorphine treatment; referring patients to psychosocial treatment; and ensuring access to naloxone for opioid overdose reversal.Conclusions: Included guidelines were informed by studies with various levels of rigor and quality. Future research should systematically study buprenorphine and methadone initiation and titration among people using fentanyl and people with pain, especially during hospitalization.


  • Open Access

    Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study

    by June-Ho Kim, Danielle R. Fine, Lily Li, Simeon D. Kimmel, Long H. Ngo, Joji Suzuki, Christin N. Price, Matthew V. Ronan, Shoshana J. Herzig

    Patients with opioid use disorder (OUD) who are hospitalized for serious infections requiring prolonged intravenous antibiotics may face barriers to discharge, which could prolong hospital length of stay (LOS) and increase financial burden. We investigated differences in LOS, discharge disposition, and charges between hospitalizations for serious infections in patients with and without OUD. We utilized the 2016 National Inpatient Sample—a nationally representative database of all discharges from US acute care hospitals. The population of interest was all hospitalizations for infective endocarditis, epidural abscess, septic arthritis, or osteomyelitis. The exposure was OUD, and the primary outcome was LOS until discharge, assessed by using a competing risks analysis to estimate adjusted hazard ratios (aHRs). Adjusted odds ratio (aOR) of discharge disposition and adjusted differences in hospital charges were also reported. Of 95,470 estimated hospitalizations for serious infections (infective endocarditis, epidural abscess, septic arthritis, and osteomyelitis), the mean age was 49 years and 35% were female. 46% had Medicare (government-based insurance coverage for people age 65+ years), and 70% were non-Hispanic white. After adjustment for potential confounders, OUD was associated with a lower probability of discharge at any given LOS (aHR 0.61; 95% CI 0.59–0.63; p < 0.001). OUD was also associated with lower odds of discharge to home (aOR 0.38; 95% CI 0.33–0.43; p < 0.001) and higher odds of discharge to a post-acute care facility (aOR 1.85; 95% CI 1.57–2.17; p < 0.001) or patient-directed discharge (also referred to as “discharge against medical advice”) (aOR 3.47; 95% CI 2.80–4.29; p < 0.001). There was no significant difference in average total hospital charges, though daily hospital charges were significantly lower for patients with OUD. Limitations include the potential for unmeasured confounders and the use of billing codes to identify cohorts. Our findings suggest that among hospitalizations for some serious infections, those involving patients with OUD were associated with longer LOS, higher odds of discharge to post-acute care facilities or patient-directed discharge, and similar total hospital charges, despite lower daily charges. These findings highlight opportunities to improve care for patients with OUD hospitalized with serious infections, and to reduce the growing associated costs.